Xenetic Biosciences (NASDAQ:XBIO) Trading Down 0.3% – Here’s What Happened

Xenetic Biosciences, Inc. (NASDAQ:XBIO) shares were down 0.3% during mid-day trading on Tuesday . The company traded as low as $3.00 and last traded at $3.08. Approximately 5,946 shares were traded during trading, a decline of 57% from the average daily volume of 13,713 shares. The stock had previously closed at $3.09.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Xenetic Biosciences has an average rating of “Sell”.

Xenetic Biosciences Stock Performance

The business’s 50-day moving average is $3.11 and its two-hundred day moving average is $2.66. The stock has a market capitalization of $7.05 million, a PE ratio of -2.57 and a beta of 2.19.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. Xenetic Biosciences had a negative net margin of 70.03% and a negative return on equity of 39.28%. The firm had revenue of $0.81 million during the quarter.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC acquired a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent reporting period. 15.12% of the stock is owned by hedge funds and other institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.